Last reviewed · How we verify
NCT02806011
Long-term Follow-up Study of Livercellgram in Alcoholic Liver Cirrhosis Patients Who Completed Livercellgram Phase 2 Study
trial in Alcoholic Liver Cirrhosis in 48 participants. Completed in 1 October 2020.
1 October 2020
Quick facts
| Lead sponsor | Pharmicell Co., Ltd. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 48 |
| Start date | 1 May 2016 |
| Primary completion | 1 October 2020 |
| Estimated completion | 1 October 2020 |
| Sites | 1 location across South Korea |
Conditions studied
- Alcoholic Liver Cirrhosis — all drugs for Alcoholic Liver Cirrhosis →
Sponsor
Pharmicell Co., Ltd. — full company profile →
Who can join
Adults 20 to 70, any sex, with Alcoholic Liver Cirrhosis. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Safety Evaluation assessed by Tumor Marker Test, Adverse Events and Serious Adverse Events, Clinical Laboratory Tests, Vital Signs, and Physical Examinations
Time frame: 5-year(+30 days)
1. Tumor Marker Test 2. Occurrence of Adverse Events and Serious Adverse Events 3. Clinical Laboratory Tests 4. Vital Sign 5. Physical Examinations
Sponsor's own description
This is a 5-year (+30 days) long term follow up study to evaluate the safety of Livercellgram in subject who participated in and completed the Livercellgram Phase 2 trials (refer to ClinicalTrials.gov.Identifier: NCT01875081).
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Clinical trials using mesenchymal stem cells in liver diseases and inflammatory bowel diseases.
Tsuchiya A, Kojima Y, Ikarashi S, Seino S, et al · · 2017 · cited 60× · PMID 29259715 · DOI 10.1186/s41232-017-0045-6 -
Cell-based liver therapies: past, present and future.
Iansante V, Chandrashekran A, Dhawan A. · · 2018 · cited 32× · PMID 29786563 · DOI 10.1098/rstb.2017.0229
Verify or expand the search:
- PubMed search for NCT02806011
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Pharmicell Co., Ltd. trials
Trials by the same sponsor.
- NCT07431008 — Safety Follow-up Study of Cellgram-ED in Post-Radical Prostatectomy Erectile Dysfunction · recruiting
- NCT07400458 — Long-term Follow-up Study Following the Approval of Hearticellgram-AMI Administration · NA · recruiting
- NCT05042206 — Clinical Trial to Evaluate Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cell in Chronic Kidney Disease · Phase 1 · completed
- NCT05093881 — Long-term Follow-up of Patients With Alcoholic Liver Cirrhosis Who Had Administered Cellgram-LC in PMC-P-07 Study · NA · recruiting
- NCT04615845 — Safety Evaluation of Autologous Dendritic Cell Anticancer Immune Cell Therapy (Cellgram-DC-PC) · Phase 1 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02806011 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Pharmicell Co., Ltd.
- Last refreshed: 29 October 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02806011.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing